IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Holdings Decreased by B. Riley Wealth Advisors Inc.

B. Riley Wealth Advisors Inc. lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 43.6% in the 3rd quarter, Holdings Channel reports. The fund owned 933 shares of the company’s stock after selling 722 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in IDEXX Laboratories were worth $466,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in IDXX. Oddo BHF Asset Management Sas purchased a new stake in shares of IDEXX Laboratories in the third quarter valued at $1,128,000. American Trust acquired a new position in IDEXX Laboratories during the third quarter valued at $757,000. Franklin Resources Inc. lifted its stake in IDEXX Laboratories by 2.5% in the 3rd quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company’s stock worth $675,259,000 after acquiring an additional 34,305 shares in the last quarter. Tidal Investments LLC boosted its position in IDEXX Laboratories by 7.6% during the 3rd quarter. Tidal Investments LLC now owns 6,310 shares of the company’s stock worth $3,188,000 after acquiring an additional 444 shares during the period. Finally, Sanctuary Advisors LLC grew its stake in IDEXX Laboratories by 20.4% during the 3rd quarter. Sanctuary Advisors LLC now owns 3,288 shares of the company’s stock valued at $1,661,000 after acquiring an additional 558 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Trading Down 0.4 %

Shares of IDXX stock opened at $409.03 on Friday. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The company has a market cap of $33.49 billion, a PE ratio of 39.44, a price-to-earnings-growth ratio of 3.99 and a beta of 1.37. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The business’s 50 day moving average is $435.18 and its two-hundred day moving average is $469.56.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm had revenue of $975.50 million for the quarter, compared to the consensus estimate of $980.32 million. During the same quarter last year, the firm posted $2.53 EPS. The business’s quarterly revenue was up 6.6% on a year-over-year basis. Equities analysts predict that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, November 28th. JPMorgan Chase & Co. dropped their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Barclays dropped their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Leerink Partners initiated coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price on the stock. Finally, Stifel Nicolaus dropped their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research report on Thursday, October 10th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $539.63.

Insider Transactions at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now owns 905 shares in the company, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.